āĻšā§āĻŽNVO âĸ NYSE
add
Novo Nordisk A/S
ā§Ŧā§Ģ.ā§Ŧā§Ļ$
āĻāĻŖā§āĻāĻž āĻĒāϰā§:(ā§Ļ.⧍ā§Ļ%)+ā§Ļ.ā§§ā§Š
ā§Ŧā§Ģ.ā§ā§Š$
āĻŦāύā§āϧ āĻāĻā§: ā§§ āĻŽā§, ā§:ā§Ģā§Ž:ā§Ēā§Š PM GMT -ā§Ē · USD · NYSE · āĻĄāĻŋāϏāĻā§āϞā§āĻŽāĻžāϰ
āĻŽāĻžāϰā§āĻāĻŋāύ āϝā§āĻā§āϤāϰāĻžāώā§āĻā§āϰ-āĻ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āϏāĻŋāĻāĻŋāĻāϰāĻŋāĻāĻŋDK-āĻ āĻšā§āĻĄāĻā§ā§āĻžāϰā§āĻāĻžāϰ
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
ā§Ŧā§Ŧ.ā§Ēā§Ģ$
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
ā§Ŧā§Ē.ā§§ā§Ž$ - ā§Ŧā§Ž.ā§Žā§Š$
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
ā§Ģā§.ā§Ļā§Ļ$ - ā§§ā§Ēā§Ž.ā§§ā§Ģ$
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
⧍⧍⧍.ā§§ā§ĒāĻā§ USD
āĻāĻĄāĻŧ āĻāϞāĻŋāĻāĻŽ
⧝ā§Ē.ā§Ļā§ŠÂ āϞāĻž
āĻāĻŦāϰ⧠āϰā§ā§āĻā§
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
(DKK) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ā§Žā§Ģ.ā§Ŧā§ŽāĻļāĻ¤Â āĻā§ | ā§Šā§Ļ.ā§Ļ⧝% |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ā§Šā§§.ā§Ļā§ĒāĻļāĻ¤Â āĻā§ | ā§§ā§Š.ā§¨ā§Ž% |
āύā§āĻ āĻāύāĻāĻžāĻŽ | ā§¨ā§Ž.ā§¨ā§ŠāĻļāĻ¤Â āĻā§ | ā§¨ā§Ž.ā§Ģā§Š% |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | ā§Šā§¨.⧝ā§Ģ | -ā§§.⧍ā§Ļ% |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | ā§Ŧ.ā§Šā§Ē | ⧍⧝.⧧⧍% |
EBITDA | ā§Ēā§Ē.⧍ā§āĻļāĻ¤Â āĻā§ | ā§Ēā§Ģ.⧝ā§Ļ% |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | ⧍ā§Ļ.ā§Ŧā§§% | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
(DKK) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ⧍ā§Ŧ.ā§Šā§§āĻļāĻ¤Â āĻā§ | -⧧⧍.⧝ā§% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ā§Ēā§Ŧā§Ģ.ā§Žā§ĻāĻā§ | ā§Ēā§Ž.ā§§ā§§% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§Šā§¨ā§¨.ā§Šā§§āĻā§ | ā§Ģā§Ģ.ā§Ļā§§% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§§ā§Ēā§Š.ā§Ē⧝āĻā§ | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ā§Ēā§Ēā§Ē.ā§§ā§Ļ āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | ⧍.ā§Ļā§Ŧ | â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | ⧍ā§Ē.ā§Ŧā§Ŧ% | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | ā§Ģā§Ļ.⧍ā§Ē% | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
(DKK) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | ā§¨ā§Ž.ā§¨ā§ŠāĻļāĻ¤Â āĻā§ | ā§¨ā§Ž.ā§Ģā§Š% |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | ⧧⧍.ā§Šā§ĻāĻļāĻ¤Â āĻā§ | ā§¨ā§Ž.ā§ā§¯% |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -⧝⧧.⧍⧍āĻļāĻ¤Â āĻā§ | -ā§Ģ⧧⧝.ā§Žā§Ļ% |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | ā§Šā§Ŧ.ā§Žā§ĒāĻļāĻ¤Â āĻā§ | ā§Ēā§Ŧā§Ē.ā§§ā§Š% |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | -ā§Ēā§§.ā§Šā§ŦāĻļāĻ¤Â āĻā§ | -ā§§ā§Ŧā§.ā§Ļā§§% |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| -ā§Šā§Ļ.ā§Ģā§Ē āĻā§ | ⧝ā§.ā§Žā§§% |
āϏāĻŽā§āĻĒāϰā§āĻā§
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in BagsvÃĻrd, with production facilities in nine countries and affiliates or offices in five. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Novo Nordisk makes the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt, denoted by the hieroglyph đ. Wikipedia
āϏāĻŋāĻāĻ
āϏā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§ā§āĻā§
⧍⧧ āĻĄāĻŋāϏā§, ā§§ā§¯ā§¨ā§Š
āϏāĻĻāϰ āĻĻāĻĒā§āϤāϰ
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
ā§ā§Ŧ,ā§Žā§¨ā§Ŧ